Unexplained weight loss (UWL), defined as a loss of 5% body weight over a period of 6 to 12 months without a clear etiology, presents a significant diagnostic challenge in clinical practice. Its differential diagnosis is vast, ranging from malignancies to psychiatric disorders, making a comprehensive approach imperative for effective patient management.
Firstly, a thorough history and physical examination is crucial, focusing on dietary changes, gastrointestinal symptoms, and systemic signs. Consideration should also be given to medications and their potential side effects. If initial investigations are unrevealing, broad-spectrum laboratory tests including complete blood count, metabolic panel, thyroid function tests, and inflammatory markers should be conducted.
If no diagnosis is reached after the above steps, imaging studies may be warranted. Abdominal ultrasound or CT scan can reveal malignancies or chronic diseases. Endoscopy or colonoscopy should be considered for persistent gastrointestinal symptoms. Specialized tests like HIV testing or tuberculosis screening may be considered based on epidemiological risk factors.
Psychiatric illnesses, particularly depression and eating disorders, can often manifest as UWL. A careful psychosocial history, ideally with the input of a mental health professional, is thus essential. Additionally, social determinants of health, such as food insecurity, should not be overlooked.
For patients with UWL where no cause is found, a watchful waiting approach may be appropriate. Regular follow-ups and monitoring for the emergence of new symptoms can guide further investigations and management.
In conclusion, a meticulous, step-wise approach to UWL can help clinicians navigate the diagnostic complexities and ensure optimal patient care. The process not only involves a comprehensive medical examination but also considers psychosocial factors, emphasizing the importance of holistic care in clinical practice.
1.
Alzheimer's Blood Test Gets FDA Clearance
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
4.
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
5.
AI tool identifies women at high risk of interval breast cancer
1.
Personalized Survivorship Navigation in Precision Cancer Care
2.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
3.
Evolution of Cancer Care Through Developmental Therapeutics
4.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
5.
Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation